Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026
Dermata expects its cash resources to fund operations into the first quarter of 2027, ahead of its planned second-product launch.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dermata Therapeutics (DRMA) reported its first commercial product sales in the third quarter of 2026 following the launch of Tome Foundational Treatment. Launched August 25, the product generated $74,000 in net sales and $40,000 in gross profit, with an approximate 54% margin. Approximately 30% of orders came through subscriptions.
Quarterly net loss widened to $2.821 million from $1.691 million a year earlier as selling, general and administrative expenses increased. Cash, cash equivalents and restricted cash totaled $5.0 million at September 30, down from $7.5 million at year-end; Dermata expects funding to last into the first quarter of 2027. A completed cosmetic study found overall skin-appearance improvement in more than 71% of participants after one treatment. Dermata enrolled the first participant in its Tome Clearing Treatment trial and expects a first-half 2027 launch, subject to successful development and commercialization.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointATM financing provided approximately $2.0 million in net proceeds during the nine months ended September 30, 2026. 52% of market cap
- Major pointAugust 2026 financing provided $3.2 million in net proceeds. 84% of market cap
- Moderate pointThird-quarter net sales reached $74,000, compared with no sales in the prior-year quarter.
- Moderate pointQuarterly research and development expenses fell to $143,000 from $504,000 a year earlier.
- Minor pointTome Foundational Treatment's August 25, 2026 launch established Dermata's first commercial product revenue.
9 minor points
- Minor pointThird-quarter gross profit reached $40,000, reflecting an approximate 54% margin.
- Minor pointSubscriptions generated approximately 30% of orders for Tome Foundational Treatment.
- Minor pointNine-month research and development expenses fell to $739,000 from $2.403 million a year earlier.
- Minor pointQuarterly loss per share narrowed to $0.55 from $1.65; weighted average shares rose to 5,119,529 from 1,026,457.
- Minor pointNine-month loss per share narrowed to $1.76 from $6.64; weighted average shares rose to 4,338,149 from 858,015.
- Minor pointCompleted cosmetic study found more than 71% of participants had overall skin-appearance improvement after one treatment.
- Minor pointTome Clearing Treatment trial enrolled its first participant in October 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Dermata expects to launch Tome Clearing Treatment in the first half of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Dermata plans to expand Tome Foundational Treatment into professional skincare channels for in-office use and recommendations.
Negative
- Major pointQuarterly net loss widened to $2.821 million from $1.691 million a year earlier.
- Moderate pointCash, cash equivalents and restricted cash fell to $5.0 million from $7.5 million at year-end.
- Moderate pointOperating activities used $7.6 million during the nine months ended September 30, 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Dermata expects current cash resources to fund operations only into the first quarter of 2027.
- Moderate pointQuarterly selling, general and administrative expenses rose to $2.755 million from $1.256 million a year earlier.
- Moderate pointShareholders' equity declined to $3.905 million from $6.223 million at December 31, 2025.
4 minor points
- Minor pointNine-month net loss widened to $7.636 million from $5.697 million a year earlier.
- Minor pointNine-month selling, general and administrative expenses rose to $7.099 million from $3.470 million a year earlier.
- Minor pointTotal liabilities increased to $2.730 million from $1.641 million at December 31, 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Tome Clearing Treatment's planned launch remains subject to successful development and commercialization activities.
Key Figures
- Cash, cash equivalents and restricted cash
- $5.0 million
- As of September 30, 2026
- Cash used in operations
- $7.6 million
- Nine months ended September 30, 2026
- Cash runway
- Into the first quarter of 2027
- Company's stated expectation based on current cash resources
- Net sales
- $74,000
- Third quarter 2026; Tome Foundational Treatment
- Gross profit
- $40,000
- Third quarter 2026
- Net loss
- $2.821 million
- Third quarter 2026
- Cosmetic study participants
- 31 participants
- Tome Foundational Treatment study
- Participants graded as improved
- More than 71%
- Overall skin appearance after one treatment
Previous Earnings Reports
-
Q2 cash of $4.4 million was expected to fund operations into Q4 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hyperpigmentation medical
salicylic acid medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / November 10, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions focused on the development and commercialization of consumer and professional skincare products, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2026.
"The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient, consisting of
"Importantly, our strategy extends beyond the launch of a single product. Recently, we initiated a clinical trial evaluating Tome Clearing Treatment, our second planned commercial product for the treatment of acne, which we expect to launch in the first half of 2027," continued Mr. Proehl.
"Looking ahead, our priorities are focused on increasing brand awareness of Tome, converting consumer interest into sales, expanding our distribution opportunities, and building a broader portfolio of products powered by Bioneedle. We believe our combination of clinical expertise, differentiated skincare technology, and direct-to-consumer commercialization provides an opportunity to build a growing skincare business with multiple potential revenue streams and create long-term value for our shareholders," concluded Mr. Proehl.
Recent Corporate Highlights
- Launched Tome Foundational Treatment and generated revenue. On August 25, 2026, Dermata officially launched Tome Foundational Treatment, its first commercial skincare product, through its direct-to-consumer website. The launch represents a significant milestone in the Company's strategic transition to commercial skincare and provides Dermata with its first opportunity to generate revenue from product sales. Tome Foundational Treatment is a once-weekly skin renewal treatment powered by the Company's Bioneedle technology and is designed to improve the appearance of skin tone, texture, fine lines, and dark spots.
- Announced positive topline results from cosmetic clinical study of Tome Foundational Treatment. In October 2026, Dermata announced positive topline results from its completed cosmetic clinical study evaluating Tome Foundational Treatment in 31 participants over four weeks. The study demonstrated improvements across multiple investigator-assessed measures of skin appearance, including fine lines, hyperpigmentation, radiance, and overall appearance. More than
71% of participants were graded as having overall improvement in skin appearance after just one treatment. The Company believes these results support Tome's positioning as "studied skincare" and provides clinically supported content to enhance consumer education, strengthen brand credibility, and support future marketing efforts. - Continued building brand awareness and market visibility for Tome. Surrounding the Tome Foundational Treatment commercial launch, Dermata has focused on introducing Tome to consumers through digital marketing, social media, public relations, and editorial outreach. The Company believes that building awareness of Tome's Bioneedle technology and once-weekly application format will be important in supporting customer acquisition and expanding its presence in the premium skincare market.
- Advanced development of second commercial skincare product for acne. In October 2026, Dermata announced enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, its second planned commercial product. Tome Clearing Treatment combines salicylic acid, an FDA-recognized over-the-counter acne active ingredient, with the Company's Bioneedle technology in a once-weekly treatment regimen for the treatment of acne. The Company expects to launch Tome Clearing Treatment in the first half of 2027, subject to successful development and commercialization activities. Dermata believes the addition of a second product could expand its addressable consumer market, create cross-selling opportunities, and diversify its commercial revenue base.
Anticipated Upcoming Milestones
- Drive commercial growth of Tome Foundational Treatment. The Company plans to continue executing its direct-to-consumer marketing strategy to increase brand awareness, attract new customers, and encourage repeat purchases. Dermata intends to leverage clinical study results, consumer education, and digital marketing to communicate the benefits of its Bioneedle technology and support future sales growth.
- Expand Tome's professional skincare presence. Dermata intends to expand opportunities to introduce Tome Foundational Treatment to aestheticians, dermatologists, and other skincare professionals for in-office use and recommendations to their clients and patients. The Company believes professional adoption could provide an additional revenue opportunity while supporting broader consumer awareness and credibility of the Tome brand.
- Advance Tome Clearing Treatment toward commercial launch in the first half of 2027. Dermata plans to continue its clinical evaluation of Tome Clearing Treatment, with the goal of generating evidence of its effect on acne to support its planned commercialization. The Company believes its second product will expand Tome's portfolio into the large consumer acne market and support the Company's strategy of building a multi-product skincare business.
- Continued optimization of commercial operations and revenue opportunities. As Dermata progresses through its initial commercialization period, the Company plans to evaluate customer purchasing patterns, subscription participation, marketing performance, and other commercial metrics to inform its growth strategy and capital allocation decisions.
Third Quarter 2026 Financial Results
As of September 30, 2026, the Company had
Net sales and cost of sales were
Research and development expenses were
Selling, general and administrative expenses were
About Tome Skincare
Tome is Dermata's skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in science and history. Tome consists of skincare products utilizing a wild harvested freshwater sponge that has evolved over centuries for consumers compelled by history and science to find potent natural products for their skincare routine. Dermata believes its Tome skincare line can simplify existing skincare routines with essential ingredients designed to deliver results, without harmful extremes.
Start your skincare story at Tome.
About Dermata Therapeutics
Dermata Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of both direct-to-consumer and professional skincare solutions. The Company leverages its experience in clinical dermatology and its Bioneedle technology to develop differentiated skincare products designed to address a variety of consumer skincare needs. Dermata's first commercial product, Tome Foundational Treatment, is now available at Tome, with additional innovations planned to follow. Dermata is headquartered in San Diego, California.
For more information, please visit Dermata.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations, and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to prioritize direct-to-consumer (DTC) and over-the-counter (OTC) skincare products; the anticipated benefits of Dermata's strategic shift to prioritize DTC and OTC skincare products, including acceleration of its path to commercialization, and expansion into broader consumer markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Clearing Treatment; the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the Company's products and their ability to generate revenue for the Company; the Company's expectations with regard to current cash, cash equivalents, and restricted cash and the amount of time it will fund operations; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
DERMATA THERAPEUTICS, INC.
Balance Sheets
In thousands USD | September 30, 2026 | December 31, 2025 | ||||||
| (unaudited) | ||||||||
Cash and cash equivalents | $ | 4,822 | $ | 7,522 | ||||
Restricted cash | 200 | - | ||||||
Prepaid expenses and other current assets | 583 | 342 | ||||||
Inventories | 825 | - | ||||||
Non-current assets | 205 | - | ||||||
Total assets | 6,635 | 7,864 | ||||||
Liabilities | ||||||||
Accounts payable | 1,620 | 461 | ||||||
Accrued liabilities | 1,110 | 1,180 | ||||||
Total liabilities | 2,730 | 1,641 | ||||||
Equity | 3,905 | 6,223 | ||||||
Total liabilities and equity | $ | 6,635 | $ | 7,864 | ||||
DERMATA THERAPEUTICS, INC.
Statements of Operations
(unaudited)
| Quarter Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
In thousands, except share and per share data | 2026 | 2025 | 2026 | 2025 | ||||||||||||
Net sales | $ | 74 | $ | - | $ | 74 | $ | - | ||||||||
Cost of sales | (34 | ) | - | (34 | ) | - | ||||||||||
Gross profit | 40 | - | 40 | - | ||||||||||||
Operating expenses | ||||||||||||||||
Research and development (1) | 143 | 504 | 739 | 2,403 | ||||||||||||
Selling, general and administrative (1) | 2,755 | 1,256 | 7,099 | 3,470 | ||||||||||||
Total operating expenses | 2,898 | 1,760 | 7,838 | 5,873 | ||||||||||||
Loss from operations | (2,858 | ) | (1,760 | ) | (7,798 | ) | ###### | |||||||||
Interest income | 37 | 69 | 162 | 176 | ||||||||||||
Net loss | $ | (2,821 | ) | $ | (1,691 | ) | $ | (7,636 | ) | $ | (5,697 | ) | ||||
Net loss per common share, basic and diluted | $ | (0.55 | ) | $ | (1.65 | ) | $ | (1.76 | ) | $ | (6.64 | ) | ||||
Weighted average common shares outstanding, basic and diluted | 5,119,529 | 1,026,457 | 4,338,149 | 858,015 | ||||||||||||
(1) Includes the following stock-based compensation expense | ||||||||||||||||
Research and development | $ | 4 | $ | 8 | $ | 22 | $ | 24 | ||||||||
Selling, general and administrative | $ | 38 | $ | 30 | $ | 105 | $ | 90 | ||||||||
Investor Contact:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Dermata's third-quarter 2026 sales and earnings?
Dermata recorded $74,000 in net sales and a $2.821 million net loss for the quarter ended September 30, 2026. Net loss was $0.55 per common share, basic and diluted, compared with a $1.691 million loss, or $1.65 per share, in the prior-year quarter.
When does Dermata expect to launch Tome Clearing Treatment?
Dermata expects to launch Tome Clearing Treatment in the first half of 2027, subject to successful development and commercialization activities. The first participant entered its clinical trial in October 2026.
How large was Dermata's Tome Foundational Treatment cosmetic study?
The completed cosmetic study evaluated 31 participants over four weeks. Investigator assessments covered fine lines, hyperpigmentation, radiance and overall appearance. More than 71% of participants were graded as having overall improvement in skin appearance after one treatment.
Why did Dermata's selling, general and administrative expenses rise in the third quarter of 2026?
Dermata attributed the increase primarily to its shift toward commercialization. Marketing and other commercialization expenses increased by $0.2 million, compensation expense increased by $0.5 million primarily through reassigned employee duties, and legal fees increased by $0.8 million due to ongoing litigation and new trademarks.